A new combination of idarubicin, etoposide and cytarabine in untreated acute non-lymphoblastic leukemia

Angelo M. Carella, Eugenia Gaozza, Gabriell Piatti, Sandro Nati, Ester Pungoltno, Gino Santini, Domenico Giordano, Raffaella Cerri, Marco Risso, Edoardo Rossi, Mauro Spriano, Angela Coingiu, Paolo Carlier, Maria R. Raffo, Eugenio Damagio, Andrea Bacigalupo, Alberto M. Marmont

Research output: Contribution to journalArticle


Sixty-seven unselected adult patients with untreated acute non lymphotblastic leukemia (ANLL) ranging in age from 15 to 80 years received a new induction regimen consisting of Idarubicin, Etoposide and Cytarabine. Patients who entered complete remission (CR) were then allocated to 4 courses of post remission intensification. After this, patients under 50 years of age with a compatible donor were given allogeneic bone marrow transplantation (BMT) or autologous BMT (ABMT) in those without an HLA-compatible donor; the remainder, older than 50, did not receive further therapy. Fifty-six of 67 patients (83.5% achieved CR (02.5% in young and 70.3% in old patients) and 40 (71 % after the first course. Seven patients (of whom, 6 were > 50 years) died in aplasia during the induction phase and four additional patients (all elderly) died during post-remission intensification without recurrent disease. Subsequently, the younger patients received transplants (BMT: 4 pts; ABMT: 10 pts). Twelve: of the 52 (23% who survived post remission intensification (BMT: 1; ABMT: 4; others: 7) are disease free survivors 9-67 months (median, 32 months) after achieving CR. In conclusion, this intensive chemotherapy regimen is highly effective both in young and odder patients but the post-remission intensification may be too aggressive for elderly patients.

Original languageEnglish
Pages (from-to)317-322
Number of pages6
JournalLeukemia and Lymphoma
Issue number5
Publication statusPublished - 1990


  • ANLL
  • Arac
  • Ldarubicin
  • Leukemia
  • VP 16

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A new combination of idarubicin, etoposide and cytarabine in untreated acute non-lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this